NICOX BUY – TP EUR19 NCX 470 is set to become best-in-class in Glaucoma
NICOX BUY – TP EUR19 NCX 470 is set to become best-in-class in GlaucomaNicox is an international ophthalmic company developing innovative solution to help maintain vision and improve ocular health. The company has developed a proprietary nitric-oxide (NO)-donating research platform from which have emerged multiples assets. Two of them have been out-licensed and are already on the market (Vyzulta and Zerviate). While those assets are providing valuable revenue streams, company’s potential rather lies on its clinical-stage assets, especially NCX 470 which is poised to become a best-in-class product.
Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.